Medtronic closed at $107.97 in the latest trading session, marking a +0.88% move from the prior day. This move outpaced the S&P 500's daily loss of 0.2%. At the same time, the Dow added 0.04%, and the tech-heavy Nasdaq lost 0.13%.
Coming into today, shares of the medical device company had lost 0.36% in the past month. In that same time, the Medical sector gained 8.04%, while the S&P 500 gained 7.08%.
Wall Street will be looking for positivity from MDT as it approaches its next earnings report date. This is expected to be November 19, 2019. In that report, analysts expect MDT to post earnings of $1.28 per share. This would mark year-over-year growth of 4.92%. Meanwhile, our latest consensus estimate is calling for revenue of $7.68 billion, up 2.62% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5.56 per share and revenue of $31.50 billion, which would represent changes of +6.51% and +3.09%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for MDT. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. MDT is currently a Zacks Rank #3 (Hold).
Digging into valuation, MDT currently has a Forward P/E ratio of 19.25. Its industry sports an average Forward P/E of 25.05, so we one might conclude that MDT is trading at a discount comparatively.
Investors should also note that MDT has a PEG ratio of 2.63 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. MDT's industry had an average PEG ratio of 2.46 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 104, putting it in the top 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
华尔街将从 MDT 中寻找积极的一面，因为它将接近下一个收益报告日。预计2019年11月19日。在这份报告中，分析师预计 MDT 每股收益为1.28美元。这将标志着同比增长4.92%。与此同时，我们最新的普遍预期是，营收为76.8亿美元，较上年同期增长2.62%。
我们的 Zacks 共识预期全年每股收益为5.56美元，收入为315亿美元，分别较上年变动+6.51%和+3.09%。
投资者还可能注意到 MDT 分析师估计的近期变化。最近的修订往往反映了近期的商业趋势。考虑到这一点，我们可以将正面的估计修正视为对公司商业前景持乐观态度的迹象。
根据我们的研究，我们认为这些估计的修正与近团队的股票变动直接相关。我们开发了 Zacks 排名，以利用这一现象。我们的系统将这些估计变更考虑在内，并提供了一个清晰、可操作的评级模型。
Zacks Rank 从#1（ Strong Buy ）到#5（ Strong Sell ），经过外部审计，其业绩表现良好，自1988年以来#1股票的年均回报率为+25%。在过去的30天里，我们对 EPS 的一致预测仍然停滞不前。MDT 目前是 Zacks 排名第3（保留）。
按估值计算， MDT 目前的远期市盈率为19.25倍。该行业的平均远期市盈率为25.05，因此我们可以得出这样的结论： MDT 的交易价格相对较低。
投资者还应注意， MDT 目前的 PEG 比率为2.63。PEG 比率与广泛使用的市盈率类似，但该指标也考虑了公司的预期盈利增长率。截至昨日收盘， MDT 的行业平均 PEG 比率为2.46。
医疗产品行业是医疗行业的一部分.该集团拥有104个 Zacks 行业排名，在所有250多个行业中排名41%。
Zacks 行业排名包括从最好到最坏的顺序，平均 Zacks 排名的个别公司在每个行业。我们的研究表明，排名前50%的行业表现优于排名后半的行业，表现为2比1。
一定要遵循所有这些股票移动的指标，以及更多的 Zacks 。com 。